Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections

Next Previous
X
Search
Trial Profile

A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilastatin/imipenem/relebactam (Primary) ; Avibactam/ceftazidime; Meropenem/vaborbactam
  • Indications Enterobacteriaceae infections; Gram-negative infections; Klebsiella infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
    • 16 Jun 2022 Planned End Date changed from 31 May 2022 to 1 Oct 2023.
    • 16 Jun 2022 Planned primary completion date changed from 31 May 2022 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top